Rapporto sull’analisi delle dimensioni del mercato e dell’analisi delle quote del mercato terapeutico radiofarmaceutico | Previsioni 2031

  • Report Code : TIPRE00039172
  • Category : Pharmaceuticals
  • Status : Data Released
  • No. of Pages : 150
Buy Now

Si prevede che le dimensioni del mercato terapeutico radiofarmaceutico raggiungeranno i 7,30 miliardi di dollari entro il 2031, rispetto ai 2,71 miliardi di dollari del 2023. Si prevede che il mercato registrerà un CAGR del 13,1% nel 20232031. L'introduzione di algoritmi di intelligenza artificiale nei dispositivi di imaging di medicina nucleare per ottimizzare la pianificazione del trattamento rimarrà probabilmente una tendenza chiave nel mercato terapeutico radiofarmaceutico.

Analisi del mercato terapeutico radiofarmaceutico< /span>

I fattori determinanti sono la rapida espansione del settore dell'imaging medicale, la crescente preferenza per i farmaci personalizzati, le scoperte nelle terapie radiofarmaceutiche e i crescenti sviluppi tecnologici per migliorare le strategie di targeting, nonché i crescenti investimenti governativi. guidano principalmente le entrate del mercato delle terapie radiofarmaceutiche.

Panoramica del mercato terapeutico radiofarmaceutico

sostanze che includono isotopi radioattivi che sono usati per trattare il cancro e altre condizioni mediche sono noti come terapie radiofarmaceutiche. Al fine di ridurre al minimo i danni ai tessuti sani, questi radiofarmaci sono realizzati per mirare specificamente e fornire alte dosi di radiazioni direttamente al sito della malattia.

Il radiofarmaco Il futuro del mercato terapeutico è promettente grazie agli sviluppi nella tecnologia della medicina nucleare, alla crescente domanda di migliori alternative terapeutiche e all’aumento della prevalenza delle malattie croniche. Inoltre, si prevede che la maggiore accettazione della medicina personalizzata e delle terapie mirate supporterà l'espansione del mercato.

Approfondimenti strategici

Radiofarmaceutico Driver e opportunità del mercato terapeutico

Crescente popolarità delle terapie mirate per stimolare la crescita del mercato

La terapia mirata è la tecnica più recente e in evoluzione utilizzato per il trattamento del cancro locale e sistemico. La ricerca preclinica e gli studi clinici dimostrano che i radionuclidi che emettono alfa uccidono le cellule tumorali mirate e non danneggiano le cellule sane nelle vicinanze. 225Ac e 227Th sono tra i radioisotopi che emettono particelle alfa attaccati agli anticorpi monoclonali per riconoscere e uccidere selettivamente le cellule cancerose erogando localmente elevate dosi di radiazioni. Le radiazioni alfa sono adatte per uccidere le cellule tumorali isolate nei sistemi vascolare e linfatico e per far regredire i tumori disturbando le reti capillari tumorali per colpire e uccidere le cellule endoteliali capillari tumorali. La terapia con radio-223 dicloruro alfa è l'unico concetto approvato per il trattamento del cancro con radioisotopi interni che emettono particelle alfa. La terapia mirata con radionuclidi rientra nella categoria delle terapie mirate. Un radioterapeutico mirato somministrato per via sistemica che combina la specificità del targeting delle cellule tumorali con i noti effetti antitumorali delle radiazioni ionizzanti ha il potenziale di sradicare contemporaneamente sia la sede del tumore primario sia il cancro che si è diffuso attraverso il corpo, comprese le popolazioni di cellule maligne non rilevabili mediante imaging diagnostico. . Esistono due agenti radioimmunoterapici approvati in commercio, l'ibritumomab tiuxetano con ittrio-90 (Zevalin; Biogen-Idec Pharmaceuticals, approvato nel 2002) e il tositumomab con iodio-131 (BEXXAR, GlaxoSmithKline, approvato nel 2003), entrambi utilizzati per trattare i batteri indolenti B- linfoma cellulare e tumori correlati. Pertanto, l'uso preferito di terapie mirate nel trattamento del cancro guida la crescita del mercato terapeutico radiofarmaceutico.

Alleanza strategica tra aziende per favorire la crescita del mercatoAnalisi della quota di mercato dei radiofarmaci terapeutici per geografia

L'ambito geografico del rapporto sul mercato dei radiofarmaci terapeutici è principalmente suddiviso in cinque regioni: Nord America, Asia Pacifico, Europa, Medio Oriente e Africa e Sud & America Centrale.

Il Nord America ha dominato il mercato terapeutico dei radiofarmaci. L'impegno della regione nei confronti dell'innovazione tecnologica e l'adozione di modalità di imaging all'avanguardia consolidano la sua posizione preminente nel campo delle terapie radiofarmaceutiche. I radiofarmaci mirati per uso terapeutico rilasciano radionuclidi direttamente ai tumori in qualsiasi parte del corpo e, pertanto, i radiofarmaci mirati hanno suscitato interesse nello sviluppo clinico per affrontare i tumori ovarici. Il National Cancer Institute ha utilizzato l’esperienza precedente derivante dall’uso clinico dei radiofarmaci nel cancro ovarico per sviluppare ulteriormente radiofarmaci coniugati che potrebbero essere presi in considerazione per il trattamento futuro delle pazienti con cancro ovarico chemorefrattario. Pertanto, i fattori sopra menzionati stanno contribuendo al dominio del Nord America nel mercato terapeutico radiofarmaceutico.

Novità sul mercato terapeutico radiofarmaceutico e sviluppi recenti

Il mercato terapeutico radiofarmaceutico viene valutato raccogliendo dati qualitativi e quantitativi dopo la ricerca primaria e secondaria, che include importanti pubblicazioni aziendali, dati di associazioni e database. Di seguito è riportato un elenco di sviluppi e strategie nel mercato delle terapie radiofarmaceutiche:

  • Bayer e Bicycle Therapeutics hanno avviato una collaborazione strategica per scoprire, sviluppare, produrre e commercializzare nuove terapie radionuclidiche mirate in oncologia. (Fonte: Bayer AG, comunicato stampa, 2023)
  • Novartis ha ricevuto l'approvazione della Commissione Europea per Pluvicto (INN: lutetium (177Lu) vipivotide tetraxetan), una terapia radioligante mirata. Pluvicto è stato approvato in combinazione con la terapia di deprivazione androgenica con o senza inibizione della via del recettore degli androgeni per il trattamento di pazienti adulti con antigene di membrana prostatico specifico (PSMA), carcinoma prostatico metastatico resistente alla castrazione positivo (mCRPC). (Fonte: Novartis, comunicato stampa, 2022)

Copertura e risultati del rapporto sul mercato terapeutico radiofarmaceutico

Il "Radiofarmaceutico terapeutico" Dimensioni e previsioni del mercato (2023-2031)” il rapporto fornisce un'analisi dettagliata del mercato che copre le aree seguenti:

  • Dimensioni e previsioni del mercato a livello globale, regionale e nazionale per tutti i segmenti di mercato chiave coperti dal ambito
  • Dinamiche di mercato come fattori trainanti, restrizioni e opportunità chiave
  • Principali tendenze future
  • Analisi PEST e SWOT dettagliata
  • Analisi del mercato globale e regionale che copre le principali tendenze del mercato, i principali attori, le normative e i recenti sviluppi del mercato
  • Analisi del panorama industriale e della concorrenza che copre la concentrazione del mercato, la mappa del calore analisi, attori importanti e sviluppi recenti
  • Profili aziendali dettagliati
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is the driving and restraining factors for the radiopharmaceutical therapeutic market?

The factors driving the growth of the radiopharmaceutical therapeutic market include the growing popularity of targeted therapies and the increasing prevalence of cancer. However, the short shelf-life of radiopharmaceuticals hampers the growth of the radiopharmaceutical therapeutic market.

What are radiopharmaceutical therapeutic?

Pharmaceutical substances that include radioactive isotopes that are used to treat cancer and other medical conditions are known as radiopharmaceutical therapeutics. To reduce damage to healthy tissues, these radiopharmaceuticals are made to particularly target and deliver high doses of radiation directly to the site of the disease.

Which segment is dominating the radiopharmaceutical therapeutic market?

The global radiopharmaceutical therapeutic market is segmented based on product type, therapy type, application, and end user. The radiopharmaceutical therapeutic market, by product type, is categorized into Technitium-99m, Thallium-201, Gallium-68, Iodine-131, Copper-64, and others. The Technitium-99m segment held a significant market share in 2023 and is anticipated to record the highest CAGR in the market during 2023–2031.

What are the growth estimates for the radiopharmaceutical therapeutic market till 2031?

The radiopharmaceutical therapeutic market is expected to be valued at US$ 7.30 billion in 2031.

What was the estimated radiopharmaceutical therapeutic market size in 2023?

The radiopharmaceutical therapeutic market was valued at US$ 2.71 billion in 2023.

Who are the major players in the radiopharmaceutical therapeutic market?

The radiopharmaceutical therapeutic market majorly consists of the players, including Cardinal Health, Bayer, Novartis, Jubilant DraxImage Inc., Curium, Yantai Dongcheng Pharmaceutical Group, Lantheus, Q BioMed, Telix Pharmaceuticals, and Radiopharm Theranostics.

The List of Companies - Radiopharmaceutical Therapeutic Market

  1. Cardinal Health
  2. Bayer
  3. Novartis
  4. Jubilant DraxImage Inc.
  5. Curium
  6. Yantai Dongcheng Pharmaceutical Group
  7. Lantheus
  8. Q BioMed
  9. Telix Pharmaceuticals
  10. Radiopharm Theranostics.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports